AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29382400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (61% w/v) plus chlorhexidine gluconate (1.0% solution)
Number of subjects: 51
Study 29382400 — intervention group
Group type: COMPARATOR
Intervention: Ethanol only (70% v/v)
Number of subjects: 51
Study 26752119 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for 4 weeks
Number of subjects: 80
Study 26752119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24580390 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 µg/kg morphine with 0.125% levobupivacaine
Number of subjects: 240
Study 24580390 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg/kg morphine with 0.125% levobupivacaine
Number of subjects: 240
Study 24580390 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 µg/kg morphine with 0.125% levobupivacaine
Number of subjects: 240
Study 24580390 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study 22503387 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic receptor blockade during reconsolidation
Number of subjects: 0
Study 22503387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 20714138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) meal
Number of subjects: 15
Study 20714138 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 15
Study 20714138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (HF) meal
Number of subjects: 15
Study 17039380 — intervention group
Group type: EXPERIMENTAL
Intervention: Laying on of hands by a healer
Number of subjects: 80
Study 17039380 — intervention group
Group type: COMPARATOR
Intervention: Laying on of hands by an actor
Number of subjects: 80
Study 15189383 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized evidence-based guideline
Number of subjects: 0
Study 11488317 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg inhaled salbutamol
Number of subjects: 20
Study 11488317 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg inhaled terbutaline
Number of subjects: 20
Study 9754108 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced helical CT (UHCT) interpretation by attending radiologists
Number of subjects: 103
Study 9754108 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced helical CT (UHCT) interpretation by radiology attending physicians and resident
Number of subjects: 103
Study 9754108 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced helical CT (UHCT) interpretation by urologist
Number of subjects: 103
Study 9754108 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy of UHCT interpretation
Number of subjects: 103
Study 9754108 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of UHCT scans correctly interpreted as positive
Number of subjects: 103
Study 9754108 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of UHCT scans correctly interpreted as negative
Number of subjects: 103
Study 9754108 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate cases interpretation
Number of subjects: 103
Study 7929871 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopolrestat 800 mg/day
Number of subjects: 0
Study 7929871 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopolrestat 1200 mg/day
Number of subjects: 0
Study 7929871 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopolrestat (dose range 50 to 1200 mg)
Number of subjects: 0
Study 7929871 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopolrestat
Number of subjects: 0
Study 3247253 — intervention group
Group type: EXPERIMENTAL
Intervention: DGAVP (desglycinamide‐arginine‐vasopressin)
Number of subjects: 13
Study 3247253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30096636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings on cigarette packs (Trial 1)
Number of subjects: 2868
Study 30096636 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages about toxic chemicals in cigarette smoke (Trial 2)
Number of subjects: 2868
Study 30096636 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings on cigarette packs (Trial 1)
Number of subjects: 2868
Study 30096636 — intervention group
Group type: COMPARATOR
Intervention: Messages about not littering cigarette butts (Trial 2)
Number of subjects: 2868
Study 26683485 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric chemotherapy protocol (UKALL2003)
Number of subjects: 229
Study 24885921 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable lung protective ventilation (VV)
Number of subjects: 50
Study 24885921 — intervention group
Group type: COMPARATOR
Intervention: Conventional lung protective ventilation (CV)
Number of subjects: 50
Study 22269899 — intervention group
Group type: EXPERIMENTAL
Intervention: Multichamber bag (MCB)
Number of subjects: 406
Study 22269899 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded PN made with olive oil (COM1)
Number of subjects: 406
Study 22269899 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded PN made with MCT/LCT (COM2)
Number of subjects: 406
Study 22269899 — intervention group
Group type: COMPARATOR
Intervention: Compounded PN (COM1 + COM2)
Number of subjects: 406
Study 22269899 — intervention group
Group type: COMPARATOR
Intervention: Secondary outcomes
Number of subjects: 406
Study 20592655 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise program (experimental group)
Number of subjects: 94
Study 20592655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 94
Study 18403448 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (goal: >= 45 min/day, 5 days/week)
Number of subjects: 115
Study 18403448 — intervention group
Group type: COMPARATOR
Intervention: Stretching control (1 day/week stretching classes)
Number of subjects: 115
Study 15813712 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-DP-SOS system (computer-aided disease prediction model)
Number of subjects: 0
Study 15813712 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard method)
Number of subjects: 0
Study 12067167 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐coated oxygenator with a centrifugal pump and low‐dose heparinization (100 IU/kg bolus, ACT of 180‐400 s)
Number of subjects: 90
Study 12067167 — intervention group
Group type: COMPARATOR
Intervention: Regular uncoated bypass equipment with a roller pump and full‐dose heparinization (300 IU/kg bolus, ACT > 400 s)
Number of subjects: 90
Study 12067167 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐coated perfusion circuits with full‐dose heparinization
Number of subjects: 90
Study 10800057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) administered 7-15 hours after busulphan (Bu)
Number of subjects: 36
Study 10800057 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CP) administered 24-50 hours after busulphan (Bu)
Number of subjects: 36
Study 10800057 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CP) administered after TBI
Number of subjects: 36
Study 8992907 — intervention group
Group type: EXPERIMENTAL
Intervention: General endotracheal anaesthesia
Number of subjects: 19
Study 8992907 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 19
Study 8992907 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia with sedation
Number of subjects: 19
Study 8992907 — intervention group
Group type: EXPERIMENTAL
Intervention: All anaesthetic techniques
Number of subjects: 19
Study 1677545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium infusion during isoflurane-narcotic-nitrous oxide anesthesia
Number of subjects: 0
Study 1677545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium infusion during halothane-narcotic-nitrous oxide anesthesia
Number of subjects: 0
Study 1677545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium infusion during narcotic-nitrous oxide anesthesia
Number of subjects: 0
Study 1677545 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery index after termination of vecuronium infusion
Number of subjects: 0
Study 6139572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP) administered intravenously at 6 pmol/kg/min for 15 min
Number of subjects: 7
Study 6139572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP)
Number of subjects: 7
Study 31797034 — intervention group
Group type: EXPERIMENTAL
Intervention: CIU + PA
Number of subjects: 10
Study 31797034 — intervention group
Group type: COMPARATOR
Intervention: CIU control
Number of subjects: 10
Study 31797034 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 10
Study 31494615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously
Number of subjects: 8880
Study 31494615 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 8880
Study 27684419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 0
Study 27684419 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive pressure (nCPAP)
Number of subjects: 0
Study 25990255 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mmol/kg of KHCO3 daily for 3 months
Number of subjects: 244
Study 25990255 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mmol/kg of KHCO3 daily for 3 months
Number of subjects: 244
Study 25990255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 24483776 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported recall of weight monitoring adherence (daily or more frequent weighing)
Number of subjects: 216
Study 24483776 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary-recorded weight monitoring adherence (≥80% of days)
Number of subjects: 216
Study 24483776 — intervention group
Group type: COMPARATOR
Intervention: Control group (less frequent weight monitoring)
Number of subjects: 216
Study 24483776 — intervention group
Group type: COMPARATOR
Intervention: Control group (diary-recorded adherence <80%)
Number of subjects: 216
Study 23088945 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 0
Study 23088945 — intervention group
Group type: COMPARATOR
Intervention: Noncontrast MR angiography
Number of subjects: 0
Study 20581798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium and divalproex
Number of subjects: 403
Study 17714964 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26 sealer and gutta‐percha
Number of subjects: 60
Study 17714964 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon and Epiphany
Number of subjects: 60
Study 17714964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Endo Aplicap and gutta‐percha
Number of subjects: 60
Study 17714964 — intervention group
Group type: COMPARATOR
Intervention: No obturation (Control group)
Number of subjects: 60
Study 15848645 — intervention group
Group type: EXPERIMENTAL
Intervention: T-tube
Number of subjects: 84
Study 15848645 — intervention group
Group type: COMPARATOR
Intervention: No T-tube
Number of subjects: 84
Study 12074206 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg pioglitazone
Number of subjects: 566
Study 12074206 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 566
Study 12074206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study 9806378 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 870
Study 9806378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study 9098478 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment in women Ct positive but affected by PID
Number of subjects: 369
Study 9098478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis (Ct) positive
Number of subjects: 369
Study 3728360 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 0
Study 3728360 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet
Number of subjects: 0
Study 3728360 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 30218882 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT) delivered by physiotherapists
Number of subjects: 11
Study 30218882 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 11
Study 27239706 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls First (combined psychosocial and health curriculum)
Number of subjects: 3000
Study 27239706 — intervention group
Group type: COMPARATOR
Intervention: Health Curriculum (HC)
Number of subjects: 3000
Study 27239706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3000
Study 24428466 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg daily
Number of subjects: 156
Study 24428466 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg daily
Number of subjects: 156
Study 24428466 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg daily
Number of subjects: 156
Study 24428466 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg weekly
Number of subjects: 156
Study 24428466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 23406994 — intervention group
Group type: EXPERIMENTAL
Intervention: MA (160 mg po, bid) plus thalidomide (50 mg po, bid)
Number of subjects: 102
Study 23406994 — intervention group
Group type: COMPARATOR
Intervention: MA (160 mg po, bid) alone
Number of subjects: 102
Study 21029594 — intervention group
Group type: EXPERIMENTAL
Intervention: Active γ‐IUD
Number of subjects: 1781
Study 21029594 — intervention group
Group type: COMPARATOR
Intervention: G‐Cu200
Number of subjects: 1781
Study 21029594 — intervention group
Group type: COMPARATOR
Intervention: TCu380A
Number of subjects: 1781
Study 18507658 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP challenge regimen A (08.00 h, repeated 24 h later)
Number of subjects: 26
Study 18507658 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP challenge regimen B (08.00 h, repeated 12 and 24 h later)
Number of subjects: 26
Study 18507658 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP challenge regimen C (20.00 h, repeated 12 h later)
Number of subjects: 26
Study 19735557 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 205
Study 19735557 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 205
Study 19735557 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 205
Study 19735557 — intervention group
Group type: EXPERIMENTAL
Intervention: PfHRP2 RDT
Number of subjects: 205
Study 19735557 — intervention group
Group type: EXPERIMENTAL
Intervention: PfLDH test
Number of subjects: 205
Study 19735557 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT)
Number of subjects: 205
Study 15181652 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava extract (300 mg; p.o.)
Number of subjects: 0
Study 11814535 — intervention group
Group type: EXPERIMENTAL
Intervention: mCPP (0.5 mg/kg)
Number of subjects: 14
Study 9365359 — intervention group
Group type: EXPERIMENTAL
Intervention: Total contact casts with a cast heel (TCCH)
Number of subjects: 40
Study 9365359 — intervention group
Group type: COMPARATOR
Intervention: Total contact casts with a cast boot (TCCB)
Number of subjects: 40
Study 9365359 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic XtraDepth shoes (XDS)
Number of subjects: 40
Study 8422824 — intervention group
Group type: EXPERIMENTAL
Intervention: Six small meals
Number of subjects: 12
Study 8422824 — intervention group
Group type: COMPARATOR
Intervention: Two large meals
Number of subjects: 12
Study 3568947 — intervention group
Group type: EXPERIMENTAL
Intervention: pirenzepine (PIR), 50 mg
Number of subjects: 12
Study 3568947 — intervention group
Group type: EXPERIMENTAL
Intervention: propantheline (PRO), 30 mg
Number of subjects: 12
Study 3568947 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine (CIM), 300 mg
Number of subjects: 12
Study 3568947 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (RAN), 150 mg
Number of subjects: 12
Study 3568947 — intervention group
Group type: EXPERIMENTAL
Intervention: bethanechol (BET), 25 mg
Number of subjects: 12
Study 3568947 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide (MET), 10 mg
Number of subjects: 12
Study 30851253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Cannula
Number of subjects: 50
Study 30851253 — intervention group
Group type: COMPARATOR
Intervention: Modified Nasal Hood
Number of subjects: 50
Study 29764099 — intervention group
Group type: EXPERIMENTAL
Intervention: IsoLite® system (IL)
Number of subjects: 8
Study 29764099 — intervention group
Group type: COMPARATOR
Intervention: Conventional rubber dam (RD)
Number of subjects: 8
Study 27064778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral suprapatellar injection site
Number of subjects: 0
Study 27064778 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial infrapatellar injection site
Number of subjects: 0
Study 27064778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral infrapatellar injection site
Number of subjects: 0
Study 25039547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl Rapide
Number of subjects: 115
Study 25039547 — intervention group
Group type: COMPARATOR
Intervention: Prolene
Number of subjects: 115
Study 22682149 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume-monitored regulation of ultrafiltration and dialysate conductivity (UCR)
Number of subjects: 60
Study 22682149 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume-monitored regulation of ultrafiltration and temperature (UTR)
Number of subjects: 60
Study 22682149 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 60
Study 22682149 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (UCR, UTR, Conventional)
Number of subjects: 60
Study 21155144 — intervention group
Group type: EXPERIMENTAL
Intervention: GDS₃₀
Number of subjects: 69
Study 21155144 — intervention group
Group type: EXPERIMENTAL
Intervention: GDS₁₅
Number of subjects: 69
Study 21155144 — intervention group
Group type: EXPERIMENTAL
Intervention: GDS₄(/)₅
Number of subjects: 69
Study 21155144 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical judgment
Number of subjects: 69
Study 17975480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective beta‐adrenergic blockers
Number of subjects: 0
Study 17975480 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hepatic venous pressure gradient >10 mm Hg
Number of subjects: 0
Study 17975480 — intervention group
Group type: EXPERIMENTAL
Intervention: Reductions in hepatic venous pressure gradient >10%
Number of subjects: 0
Study 15210375 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous experiments involving compulsive washing and compulsive checking
Number of subjects: 0
Study 15210375 — intervention group
Group type: EXPERIMENTAL
Intervention: New experiment involving compulsive ordering and arranging
Number of subjects: 0
Study 11718169 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin + laser therapy
Number of subjects: 0
Study 11718169 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy alone
Number of subjects: 0
Study 9620921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine
Number of subjects: 16
Study 9620921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7988608 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 132
Study 7988608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 7988608 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with congestive heart failure
Number of subjects: 132
Study 7988608 — intervention group
Group type: COMPARATOR
Intervention: Patients without congestive heart failure
Number of subjects: 132
Study 2921710 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthrinse
Number of subjects: 25
Study 2921710 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 25
Study 30248552 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital vaginal examination and speculum insertion
Number of subjects: 0
Study 30248552 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter insertion
Number of subjects: 0
Study 30248552 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter in situ for a median of 14 hours
Number of subjects: 0
Study 30248552 — intervention group
Group type: EXPERIMENTAL
Intervention: Being overseas-born
Number of subjects: 0
Study 30248552 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort during speculum insertion
Number of subjects: 0
Study 30248552 — intervention group
Group type: EXPERIMENTAL
Intervention: Inserter designation or experience
Number of subjects: 0
Study 28029063 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames intervention
Number of subjects: 73
Study 28029063 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 25448247 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional abdominal binder
Number of subjects: 13
Study 25448247 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable abdominal binder
Number of subjects: 13
Study 25448247 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tolerable abdominal compression (conventional binder)
Number of subjects: 13
Study 25448247 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tolerable abdominal compression (adjustable binder)
Number of subjects: 13
Study 25448247 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of compression to tolerable levels (conventional binder)
Number of subjects: 13
Study 25448247 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of compression to tolerable levels (adjustable binder)
Number of subjects: 13
Study 25448247 — intervention group
Group type: COMPARATOR
Intervention: No abdominal compression (control)
Number of subjects: 13
Study 24283167 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 380
Study 24283167 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA)
Number of subjects: 380